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BRIEF COMMUNICATIONS
Frasier Syndrome: A Cause of Focal Segmental
Glomerulosclerosis in a 46,XX Female
LAURIE DEMMER,* WILLIAM PRIMACK,*† VALERIE LOIK,‡
ROSALIND BROWN,* NICOLE THERVILLE,§ and KEN MCELREAVEY§
*Department of Pediatrics, University of Massachusetts Memorial Health Care, Worcester, Massachusetts;
†Fallon Clinic, Worcester, Massachusetts; ‡Department of Obstetrics & Gynecology, Baystate Medical Center,
Springfield, Massachusetts; and §Department of Human Immunogenetics, Institut Pasteur, Paris, France.
Abstract. The description of Frasier syndrome until now has
been restricted to XY females with gonadal dysgenesis, pro-
gressive glomerulopathy, and a significant risk of gonadoblas-
toma. Mutations in the donor splice site in intron 9 of the
Wilms’ tumor (WT1) gene have been shown to cause Frasier
syndrome and are distinct from WT1 exon mutations associ-
ated with Denys-Drash syndrome. The WT1 gene, which is
essential for normal kidney and gonadal development, encodes
a zinc finger transcription factor. The intron 9 alternative splice
donor site mutation seen in Frasier syndrome leads to loss of
three amino acids (1KTS isoform), thus disrupting the normal
ratio of the 1KTS/2KTS isoforms critical for proper gonadal
and renal development. This study examines two sisters with
identical intron 9 mutations. The proband carries a classic
diagnosis of Frasier syndrome with 46,XY gonadal dysgenesis,
whereas her sister has progressive glomerulopathy but a 46,XX
karyotype and normal female development. This indicates that
the proper WT1 isoform ratio is critical for renal and testicular
development, but apparently does not affect either ovarian
development or function. It is proposed that the clinical defi-
nition of Frasier syndrome should be broadened to include
46,XX females with normal genital development and focal
segmental glomerulosclerosis associated with a WT1 intron 9
donor splice site mutation. Nephrologists need to consider the
possibility of this heritable syndrome in evaluation of females
with focal segmental glomerulosclerosis and to consider their
risk for gonadal malignancy, as well as the risk for kidney
disease, gonadal dysgenesis, and malignancy in their offspring.
Frasier syndrome is a rare disease in phenotypic females who
develop nephrotic-range proteinuria in childhood, have idio-
pathic focal segmental glomerulosclerosis (FSGS), and
progress to end-stage renal disease by the second or third
decade of life (1). These patients are often diagnosed when
evaluated for primary amenorrhea since, until the current re-
port, the classic description of Frasier syndrome patients has
been limited to XY females. They have a normal sex-deter-
mining gene on the Y chromosome (SRY) but have gonadal
dysgenesis and streak gonads with a significant risk of gonado-
blastoma.
Recently, mutations of the Wilms’ tumor (WT1) gene have
been shown to cause Frasier syndrome (2). The WT1 gene is
located on chromosome 11p13 and encodes a zinc finger
transcription system essential for normal renal and genital
development and for tumor suppression. The mutation of WT1
in Frasier syndrome is distinct from the WT1 exon mutations
associated with Denys-Drash and the chromosome 11 deletion
known to cause WAGR syndrome (3). In Frasier syndrome, the
mutations reported thus far are within the intron 9 donor splice
site of WT1. These are predicted to lead to an imbalance of the
ratio of isoforms resulting from an alternative splice site lo-
cated between the third and fourth zinc fingers of WT1 (2,4).
Here we report two sisters with Frasier syndrome. The
proband has classical Frasier syndrome with FSGS and 46,XY
gonadal dysgenesis. However, her sister also has FSGS but has
a 46,XX karyotype and normal female gonadal development.
This is the first fully characterized demonstration of Frasier
syndrome in a genetic female. It demonstrates that the FSGS of
Frasier syndrome is caused by the WT1 mutation regardless of
the patient’s genetic sex; however, in contrast to the picture
seen in XY individuals, patients with a XX karyotype have
apparently normal ovarian development. Also, some cases of
FSGS in otherwise normal females may possibly be due to




The proband had asymptomatic 41 proteinuria noted during
a routine physical examination at age 7. She had no edema. Her
24-h urinary protein excretion was 3.5 g and serum albumin
was 3.5 g/dl. Serum creatinine was 0.5 mg/dl and cholesterol
301 mg/dl. She failed to respond to prednisone, and a renal
biopsy demonstrated FSGS in two of 44 glomeruli (Figure 1A).
Received April 28, 1999. Accepted July 31, 1999.
Correspondence to Dr. Laurie Demmer, Director of Genetics, Department of
Pediatrics, University of Massachusetts Memorial Health Care, 55 Lake Av-
enue North, Worcester, MA 01655. Phone: 508-856-3949; Fax: 508-856-4287;
E-mail: laurie.demmer@ummhc.org
1046-6673/1010-2215
Journal of the American Society of Nephrology
Copyright © 1999 by the American Society of Nephrology
J Am Soc Nephrol 10: 2215–2218, 1999
She had no response to an 8-wk course of oral cyclophospha-
mide. Proteinuria ranging from 2 to 5 g in 24 h persisted, and
angiotensin-converting enzyme inhibitors were prescribed. At
age 16, evaluation of primary amenorrhea revealed a 46,XY
karyotype (with presence of SRY by fluorescence in situ hy-
bridization), Tanner II breast development and unambiguous
female genitalia. Magnetic resonance imaging revealed a small
uterus with no detectable gonads. Laparoscopy revealed small
bilateral testosterone-producing hilar cell adenomas; no go-
nadal tissue was seen. At age 18, serum creatinine was 1.0
mg/dl and urine protein to creatinine ratio was 6.7.
Her sister had asymptomatic 41 proteinuria diagnosed at
age 5 yr. Renal biopsy also showed FSGS (Figure 1B). No
therapy other than angiotensin-converting enzyme inhibition
was given. She had menarche at age 11 and has regular menses.
Genitalia are unambiguous female with normal uterus and
adnexae on ultrasound. Karyotype is 46,XX. Currently at age
16 serum creatinine is 2.4 mg/dl with a urine protein to creat-
inine ratio of 9.2.
Laboratory Studies
DNA samples obtained from the proband, her sister, and her
mother were screened for mutations in WT1 by direct sequencing of
exons 7 to 10 (zinc finger domains) and exon-intron junctions (2).
Genomic DNA was extracted from blood lymphocytes using standard
techniques. PCR amplification of exon 9 was performed on genomic
DNA using the primers WT9A sense (59-TAGGGCCGAGGCTA-
GACCTTCTCTGT-39) and WT9B antisense (59-ATTCCCTCTCAT-
CACAATTTCATTCC-39). The PCR conditions were 94°C for 30 s,
47° for 30 s, and 72° for 1 min for 35 cycles. After visualization of the
PCR products by gel electrophoresis, column purification was per-
formed with Fisher Clean (Fisher Scientific, Pittsburgh, PA). Samples
were sequenced with ABI Prism Dye Sequencing kit (Perkin Elmer,
Norwalk, CT) according to the manufacturer’s instructions. Sequenc-
ing was performed on both sense and antisense stands to confirm the
presence of a mutation.
Results
Direct sequencing of the exon 9 exon/intron junction re-
vealed a cytosine-thymidine transition in one allele at position
14 of the splice donor site within intron 9 (Figure 2). This
mutation was detected in both sisters but not in their normal
mother. This change is predicted to alter the alternative splic-
ing of the KTS (K 5 lysine, T 5 threonine, S 5 serine) motif
and in a previous study the same transition was associated with
Frasier syndrome and was shown to cause a diminution of the
1KTS/2KTS isoform ratio (2,4).
Discussion
These two sisters, one 46,XY and the other 46,XX with
FSGS have an identical mutation affecting alternative splicing
of the WT1 gene. Consequently, the definition of Frasier
syndrome should be broadened to include 46,XX females with
normal genital development and FSGS associated with a WT1
intron 9 donor splice site mutation.
The origin of the mutation inherited by these two sisters
remains speculative. Both parents are reportedly without renal
disease, and there is no history of infertility or malignancy. The
mother’s blood did not show the mutation and, unfortunately,
blood from the father was not able to be obtained. Gonadal
mosiacism on the part of one of the parents is a well-described
genetic phenomenon and is the likely explanation for this
mutation appearing in two sisters.
WT1 is highly expressed in the developing kidney in the
nephrogenic zone and proximal tubules (3). It is later expressed
in the glomerular podocytes, suggesting that it may be essential
for normal terminal differentiation of the glomerulus and nor-
mal glomerular function (5). Mutations in WT1 cause other
renal syndromes. Denys-Drash (male pseudohermaphroditism,
early renal failure, and predisposition to Wilms’ tumor) (6) is
caused by a dominant negative mutation in exon 9 (7,8). Thus,
one allele is producing a normal WT1 protein product while the
mutated allele is making a defective product responsible for the
diffuse mesangial sclerosis, severe proteinuria, and early renal
failure seen in Denys-Drash. This abnormal WT1 product
hypothetically lacks a renal tumor suppressive effect. This may
lead to Wilms’ tumor formation in any cell in which the
function of the remaining WT1 allele is lost. Contiguous gene
deletion of 11p13, which includes the WT1 gene, results in
WAGR syndrome (Wilms’ tumor, aniridia, genital abnormal-
Figure 1. Section from renal biopsy of proband (A) and her sister (B) showing segmental glomerulosclerosis. Magnification, 3400.
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ities, and mental retardation) (9). The absence of the renal
tumor suppressive effect of the WT1 protein predisposes to the
high frequency of Wilms’ tumor seen in WAGR. In contrast, in
Frasier syndrome, the mutations cause an imbalance of the
KTS isoforms rather than formation of a mutated protein, and
the Wilms’ tumor suppressive effect is intact (2,4). Although
Barbosa et al. have described a nephroblastoma in one Frasier
syndrome patient, Wilms’ tumor is not commonly seen in this
syndrome (10). Perhaps the proteinuria that is the first symp-
tom of Frasier syndrome is also caused by an as yet not
understood defect in the podocyte resulting from the KTS
isoform imbalance.
Analysis of WT1 gene mutations in Frasier patients is help-
ing to elucidate the role of this gene in normal gonadal devel-
opment. WT1 knockout mice lack gonads in both sexes, dem-
onstrating that the presence of the gene is necessary for the
formation of the genital ridge prior to the differentiation of the
gonad into ovaries or testes (11). Our patients provide the first
genetic evidence that the appropriate ratio of 1KTS/2KTS
isoforms is critical for testis determination but has no apparent
effect on either ovarian development or function. How these
data fit into genetic models of sex determination remains
speculative (Figure 3). However, recent experiments indicate
that the WT1 can form a heterodimer with another protein
associated with gonad formation, the orphan nuclear receptor
SF-1 (steriodogenic factor-1) (12). SF-1 is located on human
chromosome 9q34. Mutations in SF-1 cause 46,XY gonadal
dysgenesis and also adrenal failure, which indicates that SF-1,
like WT1, plays a key role in testis formation (13). The 2KTS
isoform has a greater affinity for the SF-1 protein, and this
heterodimer can modulate the expression of mullerian inhibit-
ing substance in vitro. Another gene associated with 46,XY
gonadal dysgenesis is DAX-1 (for DSS [dosage-sensitive sex
reversal]-AHC [adrenal hypoplasia congenita] critical region
on the X chromosome gene 1) (14). Like SF-1, DAX-1 encodes
an orphan nuclear receptor localized on Xp21.3 that is neces-
sary for the development of the adrenal gland (15). Although
loss of function mutations in the gene do not appear to affect
either testis or ovarian development, two copies of the gene
(e.g., a man with an Xp21 duplication) impair testis determi-
nation, resulting in gonadal dysgenesis and a 46,XY female
phenotype (15,16). Therefore, although DAX-1 does not ap-
pear to be necessary for sex determination, overexpression of
the gene product can cause gonadal dysgenesis. WT1 KTS
isoforms can modulate the expression of murine DAX-1 ex-
pression constructs in vitro (17). Taken together, these data
suggest a direct, and an essential role for the WT1 KTS
isoforms in mammalian testis determination. Changes in the
relative amounts of WT1 isoforms in the genital ridge at the
moment of sex determination could result in: (1) inappropriate
Figure 2. (A) Nucleotide and amino acid sequence of WT1 exon 9 and exon/intron junction. Cytosine to thymidine transition at position 14
of the alternative splice donor site reduces formation of the KTS isoform. (B) Direct sequencing of the exon 9 exon/intron junction revealing
a cytosine-thymidine transition in one allele at position 14 of the splice donor site in the proband and her sister.
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interactions with the SF-1 gene product impairing testis deter-
mination; and/or (2) an overproduction of the DAX-1 gene
product leading to gonadal dysgenesis, a situation analogous to
that observed in patients with a duplication of Xp21.3, which
contains the DAX-1 gene (reviewed in reference 16).
We propose that the clinical definition of Frasier syndrome
should be broadened to include 46,XX females with normal
genital development and FSGS associated with a WT1 intron 9
splice site mutation. The XX patient is progressing to end-stage
renal disease as is expected in patients with Frasier syndrome. The
risk for gonadoblastoma in this young woman is unknown but
probably is low because of her clinically normal ovarian function.
Rather, it is thought to be the presence of streak gonads and a Y
chromosome in classical XY Frasier patients that predisposes to
gonadoblastoma. We expect transmission of the mutant WT1
gene to be autosomal dominant. Therefore, the XY offspring of
our XX patient will have a 50% likelihood of being phenotypic
female with Frasier syndrome. The XX offspring are likely to
have a 50% risk of FSGS with normal ovarian development.
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